Latest filing published 21 Nov 2025 for Madrigal Pharmaceuticals, INC., €427k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Carole Huntsman: trading record in brief
Carole Huntsman discloses dealings in Madrigal Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 20 November 2023 to 6 March 2026, the count stands at 29 filings.
On the market, this insider has only sold: 25 sales, €2.4M in total. Other entries cover 4 share grants. Since January 2026: no purchases and 3 sales on the market.
The latest filing, published on 6 March 2026, reports an open-market sale of €156k in Madrigal Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Carole Huntsman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 894 shares@ US$550.97Common StockSEC:0001628280-25-053648:0
- 3,386 shares0Common StockSEC:0001628280-25-011321:0
- 71 shares@ US$313.086.3% of flowCommon StockSEC:0001628280-25-010492:0
- 347 shares@ US$335.2432.9% of flowCommon StockSEC:0001628280-25-002680:0
- 688 shares@ US$316.9260.8% of flowCommon StockSEC:0000950170-24-130239:0
- 3,639 shares0Common StockSEC:0000950170-24-007572:0
- 7,834 shares0Common StockSEC:0000950170-23-065902:0
7 of 7 declarations
